Omkar Marathe

497 total citations
12 papers, 41 citations indexed

About

Omkar Marathe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Omkar Marathe has authored 12 papers receiving a total of 41 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in Omkar Marathe's work include Lung Cancer Treatments and Mutations (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Omkar Marathe is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Omkar Marathe collaborates with scholars based in United States, China and Belgium. Omkar Marathe's co-authors include Tara A. McCannel, Steve P. Lee, Fei Yu, Barry L. Burgess, Bradley R. Straatsma, Wei Gu, Jian Zhang, Li Liu, Kathleen N. Moore and Whitfield B. Growdon and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Omkar Marathe

9 papers receiving 40 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Omkar Marathe United States 3 28 18 15 10 6 12 41
Aliya Holland United States 4 14 0.5× 9 0.5× 9 0.6× 2 0.2× 5 0.8× 5 38
Taweevat Attaseth Thailand 3 21 0.8× 34 1.9× 15 1.0× 4 0.4× 9 1.5× 3 42
Jacquelyn M. Davanzo United States 3 30 1.1× 46 2.6× 21 1.4× 5 0.5× 4 0.7× 5 48
Sam Kanavati United Kingdom 3 9 0.3× 43 2.4× 11 0.7× 27 2.7× 5 0.8× 8 53
Sophy Denker Germany 4 20 0.7× 3 0.2× 5 0.3× 4 0.4× 1 0.2× 5 35
Maysun Hasan United States 3 26 0.9× 27 1.5× 9 0.6× 9 1.5× 7 43
Airong Yang China 5 8 0.3× 7 0.4× 20 1.3× 8 0.8× 20 3.3× 13 67
Yoshikage Inoue Japan 4 8 0.3× 2 0.1× 12 0.8× 4 0.4× 9 1.5× 10 35
Samuel M. Rubinstein United States 5 42 1.5× 16 1.1× 6 0.6× 13 2.2× 10 68
Patricio Serra-Bellver United Kingdom 6 63 2.3× 3 0.2× 30 2.0× 9 1.5× 11 72

Countries citing papers authored by Omkar Marathe

Since Specialization
Citations

This map shows the geographic impact of Omkar Marathe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omkar Marathe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omkar Marathe more than expected).

Fields of papers citing papers by Omkar Marathe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omkar Marathe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omkar Marathe. The network helps show where Omkar Marathe may publish in the future.

Co-authorship network of co-authors of Omkar Marathe

This figure shows the co-authorship network connecting the top 25 collaborators of Omkar Marathe. A scholar is included among the top collaborators of Omkar Marathe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omkar Marathe. Omkar Marathe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Hecht, J. Randolph, Jean‐Marie Michot, David J. Bajor, et al.. (2025). CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours. PubMed. 3(1). 10–10. 1 indexed citations
2.
3.
Forget, Frédéric, Serafín Morales, Nuhad K. Ibrahim, et al.. (2024). AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization.. Journal of Clinical Oncology. 42(16_suppl). TPS1125–TPS1125. 1 indexed citations
4.
5.
6.
7.
Moore, Kathleen N., Dhanusha Sabanathan, Yiqun Du, et al.. (2023). Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.. Journal of Clinical Oncology. 41(16_suppl). 3023–3023. 11 indexed citations
8.
Lacouture, Mario E., Anisha B. Patel, Nicole R. LeBoeuf, et al.. (2022). Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients.. Journal of Clinical Oncology. 40(6_suppl). TPS396–TPS396. 1 indexed citations
9.
Lacouture, Mario E., Milan J. Anadkat, Anisha B. Patel, et al.. (2022). A survey study of prevention and treatment patterns by academic and community oncologists for papulopustular, acneiform skin rash associated with epidermal growth factor receptor inhibitor (EGFRi) therapy.. Journal of Clinical Oncology. 40(16_suppl). e24083–e24083. 1 indexed citations
10.
Zhu, Viola W., Christine M. Bestvina, Gilberto Lopes, et al.. (2021). Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.. Journal of Clinical Oncology. 39(15_suppl). TPS9136–TPS9136. 2 indexed citations
11.
Marathe, Omkar, et al.. (2018). A Rare Case of Early Onset Multiple Myeloma in a 20-Year-Old Female With Factor X Inhibitor. Journal of Hematology. 7(2). 69–71. 5 indexed citations
12.
Marathe, Omkar, Steve P. Lee, Fei Yu, et al.. (2010). Ocular Response of Choroidal Melanoma With Monosomy 3 Versus Disomy 3 After Iodine-125 Brachytherapy. International Journal of Radiation Oncology*Biology*Physics. 81(4). 1046–1048. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aliya Holland Breakdown of academic impact, for papers by Taweevat Attaseth Breakdown of academic impact, for papers by Jacquelyn M. Davanzo Breakdown of academic impact, for papers by Sam Kanavati Breakdown of academic impact, for papers by Sophy Denker Breakdown of academic impact, for papers by Maysun Hasan Breakdown of academic impact, for papers by Airong Yang Breakdown of academic impact, for papers by Yoshikage Inoue Breakdown of academic impact, for papers by Samuel M. Rubinstein Breakdown of academic impact, for papers by Patricio Serra-Bellver
Rankless by CCL
2026